Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial (scientific article published on 08 November 2018)

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

Q33926135

Melanoma brain metastases: is it time to reassess the bias?

Q35214698

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites

Q35812429

Brain metastases: epidemiology and pathophysiology.

Q36282137

Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens

Q36413093

Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.

Q36939922

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Q37237228

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Q38737680

Melanoma central nervous system metastases: current approaches, challenges, and opportunities

Q38807942

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Q40408396

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

Q45953253

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

Q46394566

Comparing available criteria for measuring brain metastasis response to immunotherapy.

Q48272048

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

Q48594003

Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases

Q48823767

Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?

Q52147069

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

Q52618225

PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.

Q53488547

Phase II trials in journal of clinical oncology

Q83854262

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

brain metastasis

Q1620196

pembrolizumab

Q13896859

phase II clinical trial

Q42824440

P304

page(s)

52-60

P577

publication date

2018-11-08

P1433

published in

Journal of Clinical Oncology

Q400292

P1476

title

Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial

P478

volume

Reverse relations

cites work (P2860)

Q90142120	Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma
Q99565896	Brain metastases: lessons and challenges in the targeted therapy and immunotherapy era
Q90711858	Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
Q90436833	Complications associated with immunotherapy for brain metastases
Q92261316	Efficacy and safety of immune checkpoint blockade for brain metastases
Q98164819	Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
Q97523107	Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience
Q89604234	Epilepsy in brain metastasis: an emerging entity
Q97421387	Evolving treatment strategies of brain metastases from breast cancer: current status and future direction
Q98467275	Medical management of brain metastases
Q98613187	Melanoma brain metastases: review of histopathological features and immune-molecular aspects
Q92152067	Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Q91597744	Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
Q92293389	Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy
Q89967055	Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
Q92319984	Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System
Q89599976	Quoi de neuf en oncodermatologie ?
Q99412933	Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases
Q64067749	Targeting Molecular Pathways in Intracranial Metastatic Disease
Q90113096	The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review
Q64950574	The Potential of Astrocytes as Immune Modulators in Brain Tumors.
Q90474060	The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review
Q91709281	The impact of systemic precision medicine and immunotherapy treatments on brain metastases
Q91740514	The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis
Q89520966	The role of immunotherapy in the management of patients with renal cell carcinoma and brain metastases
Q64946218	Whole-brain helical tomotherapy with integrated boost for brain metastases in patients with malignant melanoma - final results of the BRAIN-RT trial.